X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-19 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $3.46 | -40,000 | 906,556 | -4% | -$138,400 | |||||
2026-02-18 | RXRX | Recursion Pharmaceuticals, Inc. | Taylor Ben R | CFO | S - Sale | $3.08 | -13,426 | 1,195,349 | -1% | -$41,352 | ||||||
| DM | 2026-02-17 | EXEL | Exelixis, Inc. | Smith Julie | Dir | S - Sale+OE | $44.00 | -106,539 | 20,590 | -84% | -$4,687,346 | |||||
2026-02-19 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale | $68.29 | -8,384 | 45,157 | -16% | -$572,568 | ||||||
2026-02-17 | NMRA | Neumora Therapeutics, Inc. | Aurora Daljit Singh | See Remarks | S - Sale | $3.56 | -6,165 | 82,770 | -7% | -$21,917 | ||||||
2026-02-17 | NMRA | Neumora Therapeutics, Inc. | Pinto Joshua | Pres | S - Sale | $3.54 | -5,967 | 209,950 | -3% | -$21,093 | ||||||
2026-02-17 | NMRA | Neumora Therapeutics, Inc. | Berns Paul L | See Remarks | S - Sale | $3.51 | -9,819 | 7,794,476 | 0% | -$34,459 | ||||||
2026-02-17 | NMRA | Neumora Therapeutics, Inc. | Milligan Michael Lee | See Remarks | S - Sale | $3.57 | -1,436 | 21,034 | -6% | -$5,119 | ||||||
| D | 2026-02-18 | IMCR | Immunocore Holdings Plc | Jallal Bahija | CEO | S - Sale+OE | $32.35 | -11,474 | 12,343 | -48% | -$371,184 | |||||
| D | 2026-02-18 | IMCR | Immunocore Holdings Plc | Goll John | SVP, FINANCE, CAO | S - Sale+OE | $32.35 | -698 | 653 | -52% | -$22,580 | |||||
| D | 2026-02-18 | IMCR | Immunocore Holdings Plc | St Leger Tina Amber | CHRO | S - Sale+OE | $32.35 | -1,000 | 1,119 | -47% | -$32,350 | |||||
| D | 2026-02-18 | IMCR | Immunocore Holdings Plc | Berman David M | HEAD OF R, D | S - Sale+OE | $32.35 | -5,965 | 5,859 | -50% | -$192,968 | |||||
| D | 2026-02-17 | TECH | Bio-Techne Corp | Herr Amy E. | Dir | S - Sale+OE | $59.11 | -1,976 | 2,880 | -41% | -$116,791 | |||||
| D | 2026-02-18 | DTIL | Precision Biosciences Inc | Amoroso Michael | Pres, CEO | S - Sale+OE | $3.84 | -20,559 | 243,392 | -8% | -$78,947 | |||||
| D | 2026-02-18 | DTIL | Precision Biosciences Inc | Kelly John Alexander | CFO | S - Sale+OE | $3.84 | -8,149 | 125,883 | -6% | -$31,292 | |||||
| D | 2026-02-18 | DTIL | Precision Biosciences Inc | Scimeca Dario | GC, Secretary | S - Sale+OE | $3.84 | -4,925 | 56,457 | -8% | -$18,912 | |||||
| D | 2026-02-18 | DTIL | Precision Biosciences Inc | Smith J. Jefferson | Chief Research Officer | S - Sale+OE | $3.84 | -4,925 | 129,857 | -4% | -$18,912 | |||||
2026-02-17 | SRRK | Scholar Rock Holding Corp | Marantz Jing L. | Chief Medical Officer | S - Sale | $46.53 | -4,157 | 126,012 | -3% | -$193,418 | ||||||
2026-02-17 | SRRK | Scholar Rock Holding Corp | Ho Junlin | GC | S - Sale | $46.53 | -9,580 | 241,545 | -4% | -$445,740 | ||||||
2026-02-17 | SRRK | Scholar Rock Holding Corp | Parlavecchio Caryn | CHRO | S - Sale | $46.53 | -9,035 | 169,087 | -5% | -$420,382 | ||||||
2026-02-17 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $46.53 | -7,989 | 106,929 | -7% | -$371,714 | ||||||
2026-02-17 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $52.40 | -39,404 | 126,041 | -24% | -$2,064,770 | ||||||
| D | 2026-02-17 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale+OE | $51.65 | -68,967 | 287,788 | -19% | -$3,562,417 | |||||
| D | 2026-02-18 | SLDB | Solid Biosciences Inc. | Cumbo Alexander | Pres, CEO | S - Sale+OE | $5.82 | -16,644 | 235,405 | -7% | -$96,923 | |||||
| D | 2026-02-18 | SLDB | Solid Biosciences Inc. | Hanrahan Jessie | Chief Regulatory Officer | S - Sale+OE | $5.82 | -4,134 | 74,318 | -5% | -$24,074 | |||||
| D | 2026-02-18 | SLDB | Solid Biosciences Inc. | Ganot Ilan | Dir | S - Sale+OE | $5.82 | -2,658 | 146,165 | -2% | -$15,478 | |||||
| D | 2026-02-18 | SLDB | Solid Biosciences Inc. | Herzich Paul | CTO | S - Sale+OE | $5.82 | -3,616 | 72,638 | -5% | -$21,057 | |||||
| D | 2026-02-18 | SLDB | Solid Biosciences Inc. | Howton David T | COO | S - Sale+OE | $5.82 | -7,469 | 105,077 | -7% | -$43,494 | |||||
| D | 2026-02-18 | SLDB | Solid Biosciences Inc. | Brooks Gabriel | Chief Medical Officer | S - Sale+OE | $5.82 | -0 | 89,466 | 0% | -$0 | |||||
| D | 2026-02-18 | SLDB | Solid Biosciences Inc. | Tan Kevin | CFO, Treasurer | S - Sale+OE | $5.82 | -5,404 | 99,422 | -5% | -$31,469 | |||||
| DM | 2026-02-17 | IVVD | Invivyd, Inc. | Allen Robert D. III | Chief Scientific Officer | S - Sale+OE | $1.56 | -37,581 | 114,487 | -25% | -$58,600 | |||||
| DM | 2026-02-17 | IVVD | Invivyd, Inc. | Green Julie | CHRO | S - Sale+OE | $1.56 | -40,627 | 107,717 | -27% | -$63,350 | |||||
| M | 2026-02-13 | EXEL | Exelixis, Inc. | Senner Christopher J. | EVP, CFO | S - Sale | $43.32 | -64,895 | 978,815 | -6% | -$2,810,998 | |||||
2026-02-17 | EXEL | Exelixis, Inc. | Haley Patrick J. | EVP, Commercial | S - Sale | $43.52 | -67,814 | 381,908 | -15% | -$2,950,941 | ||||||
2026-02-13 | EXEL | Exelixis, Inc. | Eckhardt Sue Gail | Dir | S - Sale | $43.79 | -3,856 | 17,524 | -18% | -$168,854 | ||||||
| DM | 2026-02-17 | IVVD | Invivyd, Inc. | Duke William E. | CFO | S - Sale+OE | $1.56 | -40,627 | 107,717 | -27% | -$63,350 | |||||
| D | 2026-02-13 | EXEL | Exelixis, Inc. | Oliver Bob | Dir | S - Sale+OE | $43.81 | -30,250 | 21,120 | -59% | -$1,325,339 | |||||
2026-02-18 | EXEL | Exelixis, Inc. | Hefti Brenda | SVP, GC | S - Sale | $44.01 | -18,669 | 102,039 | -15% | -$821,623 | ||||||
| DM | 2026-02-17 | IVVD | Invivyd, Inc. | Lee Timothy Edward | Chief Commercial Officer | S - Sale+OE | $1.56 | -40,627 | 117,717 | -26% | -$63,350 | |||||
| DM | 2026-02-17 | IVVD | Invivyd, Inc. | Andersen Jill | GC, Secretary | S - Sale+OE | $1.56 | -67,710 | 182,236 | -27% | -$105,581 | |||||
| D | 2026-02-17 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Comm, Corp Aff Officer | S - Sale+OE | $154.44 | -28,000 | 120,288 | -19% | -$4,324,228 | |||||
2026-02-17 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale | $69.51 | -11,291 | 53,541 | -17% | -$784,783 | ||||||
2026-02-17 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $154.43 | -3,000 | 167,779 | -2% | -$463,290 | ||||||
2026-02-13 | TWST | Twist Bioscience Corp | Chess Robert | Dir | S - Sale | $48.26 | -2,184 | 63,612 | -3% | -$105,402 | ||||||
2026-02-13 | VIR | Vir Biotechnology, Inc. | Sabatini Brent | SVP, Chief Accounting Officer | S - Sale | $7.79 | -1,530 | 47,872 | -3% | -$11,919 | ||||||
| D | 2026-02-17 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $16.08 | -21,000 | 4,008,762 | -1% | -$337,680 | |||||
| D | 2026-02-12 | BIIB | Biogen Inc. | Murphy Nicole | Head of Pharm Ops, Tech | P - Purchase | $195.04 | +3 | 19,611 | 0% | +$585 | |||||
2025-12-18 | KLRS | Kalaris Therapeutics, Inc. | Akkaraju Srinivas | Dir, 10% | P - Purchase | $10.42 | +479,847 | 12,948,081 | +4% | +$5,000,006 | ||||||
2026-02-17 | AURA | Aura Biosciences, Inc. | Kilroy Conor | See Remarks | S - Sale | $5.05 | -12,079 | 167,234 | -7% | -$60,999 | ||||||
2026-02-17 | AURA | Aura Biosciences, Inc. | Plavsic Mark | CTO | S - Sale | $5.05 | -15,890 | 181,397 | -8% | -$80,245 | ||||||
2026-02-17 | AURA | Aura Biosciences, Inc. | Hopkins Janet Jill | Chief Medical Officer | S - Sale | $5.06 | -20,401 | 232,284 | -8% | -$103,229 | ||||||
2026-02-17 | AURA | Aura Biosciences, Inc. | Elazzouzi Amy | SVP, Finance | S - Sale | $5.06 | -8,549 | 75,532 | -10% | -$43,258 | ||||||
2026-02-17 | AURA | Aura Biosciences, Inc. | De Los Pinos Elisabet | See Remarks | S - Sale | $5.06 | -47,648 | 537,578 | -8% | -$241,099 | ||||||
2026-02-17 | TNYA | Tenaya Therapeutics, Inc. | Higa Tomohiro | SVP, Finance | S - Sale | $0.64 | -3,469 | 119,752 | -3% | -$2,231 | ||||||
2026-02-17 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | CEO | S - Sale | $0.64 | -14,862 | 443,404 | -3% | -$9,557 | ||||||
2026-02-17 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Chief Medical Officer | S - Sale | $0.64 | -5,160 | 218,618 | -2% | -$3,319 | ||||||
| DM | 2026-02-12 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale+OE | $50.16 | -5,250 | 306,250 | -2% | -$263,359 | |||||
2026-02-12 | ENTX | Entera Bio Ltd. | Rubin Steven D | Dir | P - Purchase | $1.49 | +5,000 | 15,000 | +50% | +$7,450 | ||||||
| D | 2026-02-12 | ZIVO | Zivo Bioscience, Inc. | Strome Mark E | 10% | P - Purchase | $9.77 | +20,000 | 472,942 | +4% | +$195,400 | |||||
| D | 2026-02-12 | PALI | Palisade Bio, Inc. | Jones Mitchell Lawrence | Chief Medical Officer | S - Sale+OE | $1.75 | -1,989 | 13,263 | -13% | -$3,481 | |||||
| D | 2026-02-12 | PALI | Palisade Bio, Inc. | Finley John David | CEO, CFO | S - Sale+OE | $1.75 | -3,896 | 27,404 | -12% | -$6,818 | |||||
2026-02-11 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $63.35 | -20,000 | 1,172,987 | -2% | -$1,266,953 | ||||||
2026-02-12 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $50.00 | -7,000 | 130,031 | -5% | -$350,000 | ||||||
2026-02-12 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $12.03 | -416 | 128,219 | 0% | -$5,004 | ||||||
| M | 2026-02-11 | SRZN | Surrozen, Inc./De | Tcg Crossover Gp Ii, LLC | 10% | P - Purchase | $23.59 | +18,856 | 651,112 | +3% | +$444,844 | |||||
| D | 2026-02-11 | VCEL | Vericel Corp | McLaughlin Kevin F | Dir | S - Sale+OE | $34.66 | -7,000 | 15,100 | -32% | -$242,620 | |||||
2026-02-11 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $49.93 | -5,000 | 138,581 | -3% | -$249,650 | ||||||
| M | 2026-02-10 | TNYA | Tenaya Therapeutics, Inc. | Column Group III Gp, LP | 10% | S - Sale | $0.69 | -4,400,290 | 51,965,376 | -8% | -$3,042,222 | |||||
2026-02-11 | TECX | Tectonic Therapeutic, Inc. | Reicin Alise | CEO | P - Purchase | $21.10 | +2,500 | 362,077 | +1% | +$52,750 | ||||||
2026-02-10 | ZIVO | Zivo Bioscience, Inc. | Yaldoo Laith L | Dir, 10% | P - Purchase | $10.27 | +2,434 | 582,072 | 0% | +$24,997 | ||||||
| D | 2026-02-09 | KRYS | Krystal Biotech, Inc. | Romano Kathryn | Chief Accounting Officer | S - Sale+OE | $272.14 | -12,500 | 18,568 | -40% | -$3,401,705 | |||||
2026-02-10 | TECX | Tectonic Therapeutic, Inc. | Lochner Daniel | CFO | P - Purchase | $21.61 | +6,000 | 32,044 | +23% | +$129,660 | ||||||
2026-02-10 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO, CBO | S - Sale | $3.85 | -4,569 | 210,078 | -2% | -$17,591 | ||||||
2026-02-10 | VYGR | Voyager Therapeutics, Inc. | Sandrock Alfred | Pres, CEO | S - Sale | $3.78 | -12,192 | 509,989 | -2% | -$46,086 | ||||||
2026-02-10 | VYGR | Voyager Therapeutics, Inc. | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $3.85 | -3,525 | 153,193 | -2% | -$13,571 | ||||||
2026-02-10 | ENTX | Entera Bio Ltd. | Taitel Haya | Dir | P - Purchase | $1.48 | +7,500 | 0 | -100% | +$11,100 | ||||||
2026-02-10 | ENTX | Entera Bio Ltd. | Germano Geno J | Dir | P - Purchase | $1.49 | +20,000 | 0 | -100% | +$29,800 | ||||||
2026-02-09 | ENTX | Entera Bio Ltd. | Rubin Steven D | Dir | P - Purchase | $1.20 | +10,000 | 10,000 | New | +$12,000 | ||||||
2026-02-09 | ENTX | Entera Bio Ltd. | Ellis Sean | Dir | P - Purchase | $1.24 | +18,000 | 178,098 | +11% | +$22,320 | ||||||
| D | 2026-02-09 | BIIB | Biogen Inc. | Singhal Priya | Head of Development | S - Sale+OE | $199.83 | -2,660 | 8,043 | -25% | -$531,548 | |||||
| D | 2026-02-06 | EIKN | Eikon Therapeutics, Inc. | Column Group IV Gp, LP | 10% | P - Purchase | $18.00 | +2,117,760 | 5,780,143 | +58% | +$38,119,680 | |||||
2026-02-06 | TWST | Twist Bioscience Corp | Johannessen Jan | Dir | S - Sale | $47.91 | -2,200 | 17,754 | -11% | -$105,395 | ||||||
| D | 2026-02-04 | EIKN | Eikon Therapeutics, Inc. | Foresite Capital Management Iv, LLC | 10% | P - Purchase | $18.00 | +55,555 | 1,318,983 | +4% | +$999,990 | |||||
| D | 2026-02-04 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale+OE | $18.46 | -2,145 | 216,637 | -1% | -$39,597 | |||||
2026-02-04 | EIKN | Eikon Therapeutics, Inc. | Frazier Kenneth C | Dir | P - Purchase | $18.00 | +111,111 | 111,111 | New | +$1,999,998 | ||||||
| D | 2026-02-04 | EIKN | Eikon Therapeutics, Inc. | Wolfe Josh | Dir, 10% | P - Purchase | $18.00 | +277,776 | 2,294,653 | +14% | +$4,999,968 | |||||
| D | 2026-02-04 | EIKN | Eikon Therapeutics, Inc. | Lux Venture Partners V, LLC | 10% | P - Purchase | $18.00 | +277,776 | 2,294,653 | +14% | +$4,999,968 | |||||
2026-02-04 | SLDB | Solid Biosciences Inc. | Howton David T | COO | S - Sale | $6.44 | -18,894 | 97,859 | -16% | -$121,713 | ||||||
2026-02-04 | SLDB | Solid Biosciences Inc. | Cumbo Alexander | Pres, CEO | S - Sale | $6.44 | -48,913 | 222,018 | -18% | -$315,093 | ||||||
2026-02-04 | SLDB | Solid Biosciences Inc. | Ganot Ilan | Dir | S - Sale | $6.44 | -7,205 | 143,962 | -5% | -$46,414 | ||||||
2026-02-04 | SLDB | Solid Biosciences Inc. | Tan Kevin | CFO, Treasurer | S - Sale | $6.44 | -14,783 | 94,201 | -14% | -$95,231 | ||||||
2026-02-04 | SLDB | Solid Biosciences Inc. | Brooks Gabriel | Chief Medical Officer | S - Sale | $6.44 | -12,616 | 84,092 | -13% | -$81,271 | ||||||
2026-02-04 | SLDB | Solid Biosciences Inc. | Hanrahan Jessie | Chief Regulatory Officer | S - Sale | $6.44 | -12,348 | 70,327 | -15% | -$79,545 | ||||||
2026-02-04 | SLDB | Solid Biosciences Inc. | Herzich Paul | CTO | S - Sale | $6.44 | -10,905 | 69,067 | -14% | -$70,249 | ||||||
| D | 2026-02-04 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $4.12 | -40,000 | 933,821 | -4% | -$164,800 | |||||
2026-02-03 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $4.20 | -220,000 | 6,429,863 | -3% | -$924,000 | ||||||
2026-02-04 | TSHA | Taysha Gene Therapies, Inc. | Alam Kamran | CFO | S - Sale | $4.52 | -1,655 | 1,442,131 | 0% | -$7,481 | ||||||
| D | 2026-02-05 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale+OE | $150.00 | -115,640 | 613,912 | -16% | -$17,346,000 | |||||
| DM | 2026-02-03 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $77.07 | -50,000 | 708,719 | -7% | -$3,853,503 | |||||
2026-02-03 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $1.82 | -323 | 514,551 | 0% | -$589 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |